Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fed Condition

Recruitment & Eligibility

Inclusion Criteria

The volunteers were included in the study based on the following criteria:

Sex: male.
Age: 18 - 45 years.
Volunteer with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.
Healthy and willing to participate in the study.
Volunteer willing to adhere to the protocol requirements and to provide written informed consent.
Non-smokers or smoker who smokes less than 10 cigarettes per day

Exclusion Criteria

The volunteers were excluded from the study based on the following criteria:

Clinically relevant abnormalities in the results of the laboratory screening evaluation.
Clinically significant abnormal ECG or Chest X-ray.
Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg and diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.

Pulse rate less than 50/minute or more than 100/minute.

Oral temperature less than 95°P or more than 98.6°P.
Respiratory rate less than 12/minute or more than 20/minute
History of allergy to the test drug or any drug chemically similar to the drug under investigation.
History of alcohol or drug abuse
Positive breath alcohol test
Recent history of kidney or liver dysfunction.
History of consumption of prescribed medication since last 14 days or OTC medication since last 07 days before beginning of the study.
Volunteers suffering from any chronic illness such as arthritis, asthma etc.
History of heart failure.
HIV, HCV, HBsAg positive volunteers.
Opiate, tetra hydrocannabinol, amphetamine, barbiturates, benzodiazepines, - - - Cocaine positive volunteers based on urine test.
Volunteers suffering from any psychiatric (acute or chronic) illness requiring medications.
Administration of any study drug in the period 0 to 3 months before entry to the study.
History of significant blood loss due to any reason, including blood donation in the past 3 months.
History of pre-existing bleeding disorder.
Existence of any surgical or medical condition, which, in the judgment of the chief investigator and/or clinical investigator/physician, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of volunteers.
Inability to communicate or co-operate due to language problem, poor mental development or impaired cerebral function.

Study & Design

Primary Outcome Measures

Name	Time	Method
bioequivalence based on Composite of Pharmacokinetics		bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.

Secondary Outcome Measures

Name	Time	Method

Recruitment & Eligibility